Sensei Biotherapeutics Reports Early Data from Phase 1/2 Clinical Trial of SNS-301 in Combination with Pembrolizumab in Advanced Head and Neck Cancer Patients at ESMO 2020
BOSTON & GAITHERSBURG, Md.–(BUSINESS WIRE)–Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing personalized yet off the shelf immunotherapies for cancer and infectious diseases, announced today results from the Phase 1/2 clinical trial evaluating the safety, efficacy, and immunogenicity of SNS‑301, a first-in-class bio-engineered, inactivated bacteriophage, in patients with Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN). The data were presented in a poster discussion session at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. Read the full article here: